Pehea e hōʻoia ai i kahi mea hoʻolako Peptide Research-Grade

Pane wikiwiki

Five criteria for research-grade peptide supplier verification: identity testing, ʻano maʻemaʻe, CoA documentation, intended-use controls, māliko.

ʻanuʻu 1: Hoʻokaʻawale i ka ʻike ʻike mai ka ʻikepili maʻemaʻe

ʻelua mau heluhelu analytical ʻaoʻao-ʻaoʻao - he hōʻoia ʻike ʻike nui-spectrometry e hōʻike ana i kahi pāʻani molekala-kaumaha., a me kahi chromatogram HPLC e hōʻike ana i kahi

ʻO ka ʻike a me ka maʻemaʻe he mau nīnau hoʻokaʻawale kaʻawale, a ʻo ka mea hoʻolako e pane i hoʻokahi wale nō o lākou i pane ʻole i kekahi. Nīnau ʻo Identity i ke ʻano o ka mea: pono pono, hōʻoia orthogonal e like me mass spectrometry, LC-MS/MS, ka nānā ʻana i ka ʻakika amino, NMR, palapala palapala peptide, a i ʻole ka paʻa ʻana o ka HPLC i kahi maʻamau kuhikuhi (ʻO ka hana maʻamau ʻo USP, 2023). Hoʻokaʻawale ʻo Mass spectrometry i nā molekala ma ka ratio mass-to-charge a hōʻike i ke kaumaha molekala; Hoʻohui ʻo LC-MS/MS i kahi ʻanuʻu ʻāpana e heluhelu ana i ka ʻike kaʻina. He ana okoa ka maemae: hoʻonui ia i ka peptide pahuhopu e pili ana i nā haumia a me nā mea pili, a ʻaʻohe ʻōlelo e pili ana inā ʻo ka moleke kūpono ka pahuhopu.

ʻO kēlā āpau ke ʻano kūpono ʻole e kapa ʻia. Hiki i kahi hui ke heluhelu 99% maʻemaʻe e HPLC a ʻo ia ka peptide hewa, no ka mea, ʻaʻole hōʻike ka ʻike maʻemaʻe kiʻekiʻe. Ma ka ho'āʻo maʻemaʻe BPC-157, hōʻoia ka chromatogram maʻemaʻe i hoʻokahi ʻano mea i hoʻomalu i ka hāpana, ʻaʻole ia he BPC-157 ka ʻano.

Nā lawelawe Pehea e hōʻoia ai i kahi mea hoʻolako Peptide Research-Grade

Hoʻopili ʻia ka maʻemaʻe mai ka wahi kiʻekiʻe i hoʻohui ʻia: wahi kiʻekiʻe i hoʻopaʻa ʻia i puʻunaue ʻia e ka ʻāpana piko i hoʻohui ʻia, hoonuiia e 100. Manaʻo ka ʻaha kūkā i ka HPLC i hoʻohuli ʻia ma kahi kolamu C18 me ka ʻike UV ma 220 nm, ka lōʻihi nalu kahi e hoʻopaʻa ai nā peptide paʻa (GenScript peptide palapala palapala).

He aha e nānā: Aia i loko o ka pūʻolo palapala kahi ala ʻike (MS, LC-MS/MS, a i ʻole like) hōʻike ʻokoʻa mai ke ʻano hoʻomaʻemaʻe, a i ʻole e hōʻike ana i hoʻokahi pākēneka maʻemaʻe e like me ka moʻolelo analytical holoʻokoʻa?

Pehea e hōʻoia ai i kahi mea hoʻolako Peptide Research-Gradehale kūʻai =”https://molchanges.com/wp-content/uploads/2026/10/pub_20261002_013927_165_11203be2c7974a76b7f4d56fce8c9749.png”>

ʻanuʻu 2: Heluhelu i kahi koi maʻemaʻe no kāna hana, Lot, Lab, a me ka lā

he palapala hōʻoia no ka nānā ʻana me ka helu hailona, lā hana, lā kālailai, inoa hale hoʻokolohua, laina ala, a me ka chromatogram refe

No ka mea, he mau nīnau kaʻawale ka ʻike a me ka maʻemaʻe, ʻo ka pakeneka maʻemaʻe e lilo i mea hōʻike wale i ka wā o ke ʻano, helu hailona, hale hoʻokolohua, a me ka huakaʻi hele ʻana o ka lā loiloi me ia. ʻO kēlā mau māla ke kumu o ka hapa nui o ka palapala peptide o nā koi loiloi.

Hoʻohuihui Peptide E hoʻomaka me ke ʻano. ʻO ka hopena HPLC-UV hiki ke hoʻohuli ʻia e pale i kona lōʻihi hawewe ʻike, kolamu, a me ka gradient, a haʻi i ka maʻamau i hōʻoia ʻia. Hoʻohana ʻia kahi ʻano hana i paʻi ʻia e ka hale hana ʻaelike C18 5 µm, 4.6 × 250 mm kolamu me ka wai/acetonitrile gradient i loaʻa 0.1% TFA a i ʻole formic acid, heluhelu mua ma 214 nm me a 280 nm kaha lua, hōʻike i nā haumia a hiki i 0.1% o ka huina kiekie, a ua hōʻoia ʻia i ka ICH Q2(R1) a me USP <621> (Ho'āʻo ACS Lab, kiʻi ʻia 2026-01-01). ʻO ia kahi ala HPLC i kākau ʻia, ʻaʻole pākēneka wale nō. Inā ʻōlelo kekahi CoA "≥98% (HPLC)” a kū ma laila, ʻAʻole hiki iā ʻoe ke haʻi inā i hele mai ka helu mai kahi ala i hōʻoia ʻia a i ʻole hoʻokahi injection ma kahi ʻōnaehana uncalibrated.

ʻOi aku ka ʻokoʻa ʻelua ma mua o ka manaʻo o ka hapa nui o nā mea kūʻai: ʻAʻole ʻike ʻia kahi helu wahi-pakeneka o UV ma ke kaumaha. Hāʻawi ʻo USP i ka hoʻomaʻemaʻe peptide ma ke kaulike nui, ana i kēlā me kēia papa haumia ʻike ʻia, me nā mea haumia pili i ka peptide, counter ion, wai, koena solvents, a me na koena hiki ole ke puhi, a e unuhi ana i ka huina mai 100% (ʻO ka hana maʻamau ʻo USP, 2023). No ka mea, ʻaʻole ana ka maʻemaʻe o UV i nā counterions, TFA a i ʻole nā ​​paʻakai acetate, ʻano wai, a i ʻole nā ​​mea hoʻoheheʻe koena, Hiki ke noho pū me kahi pākēneka ʻāpana kiʻekiʻe me kahi maʻiʻo peptide ʻupena haʻahaʻa haʻahaʻa ma ke kaupaona.

A laila e nānā i ka hailona a me ka lā e pili ana i kāu kauoha ponoʻī. No ka hailona hoʻokahi i hoʻāʻo ʻia i ka lā hoʻokahi, ʻaʻole i kahi laina huahana. Ke kau ʻoe mai ka milligrams a i ka grams, noi i ke CoA o ka ʻO nā Peptides Synthetic nui kāu e loaʻa nei, a hoʻohālikelike i kona lā hōʻike i ka lā hoʻouna. He ʻumikūmāwalu mahina ma mua o ka hoʻouna ʻana, e wehewehe ana kahi CoA i kahi pūʻulu ʻokoʻa ma mua o ka pahu.

Pehea ke ano o ka hemahema: he CoA me ka pakeneka maemae, ʻaʻohe laina ala, ʻaʻohe lā hōʻike kikoʻī kikoʻī, a ʻaʻohe chromatogram. ʻAʻohe āu ala e haʻi ai inā ua ana ʻia ke kiʻi, manaʻo ʻia, a i kope ʻia mai kahi pūʻulu mua.

ʻanuʻu 3: Noi i ka Pūʻulu Palapala a nānā iā ia e kūʻē iā ALCOA+

Ke ʻike ʻoe i nā māla e pono ai kahi koi maʻemaʻe, ʻo ka hana aʻe e noi i ka pūʻolo holoʻokoʻa, no ka mea, ʻaʻole he palapala hoʻokahi ka CoA. He pūʻolo, a ʻo ka pūʻolo ka mea āu e nānā ai.

E noi i kēia mau kahua ma mua o kou loiloi ʻana i kekahi mea ʻē aʻe: helu hailona, lā hana, lā kālailai, hale hoʻokolohua, ʻano kālailai, chromatogram a i ʻole ka ʻōlelo kuhikuhi, ka hopena ʻike mass-spectrometry, kūlana mālama, a me kahi ʻōlelo kikoʻī o ka mea ʻaʻole hoao. ʻO kēlā kahua hope ka mea i waiho ʻia e nā mea hoʻolako, a ʻo kona nalo ʻana e hōʻike iā ʻoe ma mua o kona hiki ʻana. ʻO kēia ka palapala peptide koʻikoʻi o ka hoʻopaʻa ʻana i nā koi a kahi loiloi loiloi e hana ai.

E hoʻoponopono i ka pūʻolo nā hiʻohiʻona pili i ka ʻikepili ALCOA+, e koi ana i nā moʻolelo e hoʻoili ʻia, hiki ke heluhelu, hoʻokahi manawa, kumu a pololei, me ka piha, kūlike, hoʻomanawanui a loaʻa. Hoʻopau ʻia nā ʻano ʻelima kumu i ka alakaʻi FDA CGMP i Dekemaba 2018; ʻO ke alakaʻi hoʻopaʻa ʻikepili GxP o MHRA, Hoʻoponopono 1 (Malaki 2018), hoʻohui i nā mea ʻehā i koe. ʻO Contemporaneous ka hoʻāʻo e hopu i nā pūʻolo nāwaliwali loa: he lā hoʻopalekana i kūkulu hou ʻia nā mahina ma hope o ka pau ʻole o ka synthesis.

Hōʻike ʻia kahi pūʻolo kikoʻī nui mai MOL Changes i ke ʻano nānā ʻia: he hōʻike analytical i hoʻopaʻa ʻia i kahi inoa inoa, me ka ʻikepili maikaʻi loa no ka noiʻi a me ka hoʻohana ʻana i ka ʻoihana. Hoʻohana ʻo MOL Changes i ka Papa 100 hana hoʻomaʻemaʻe ultra-sterile me ka HPLC hale, MS a me ka ho'āʻo sterility, a hana i nā peptides maʻamau a me ka papa inoa mai nā milligrams a i nā kilokani.

⚠️ ʻŌlelo Aʻo: hana ʻia kahi CoA e kahi pāʻina me ka hoihoi i ka hopena; ʻO ka hoʻāʻo kūʻokoʻa ʻekolu ʻaoʻao ka mea e hoʻokiʻekiʻe ai i kona kaumaha evidentiary.

ʻanuʻu 4: E hoʻohana i nā mana i manaʻo ʻia e hoʻohana ma ke ʻano he hōʻailona hōʻoia

Hōʻike ka palapala iā ʻoe i ka mea i hoʻāʻo ʻia; ʻO nā mana i manaʻo ʻia-hoʻohana e haʻi iā ʻoe i ka manaʻo o ka mea hoʻolako no ka huahana. ʻO ka hoʻohana ʻana i ka noiʻi ʻaʻole hoʻohana i ka peptide labeling, a ʻo ka mālama ʻana iā ia ma ke ʻano he boilerplate ke ʻano o ka hoʻopau ʻana o nā mea kūʻai aku i ka mea kūʻai aku i mua o ka mea kūʻai aku. Hoʻonohonoho ʻo RUO i kahi huahana i hana ʻia a kūʻai ʻia no ka noiʻi ʻana, inā he haʻawina in vitro, hoao holoholona, kemika kālailai, a i ʻole ka hoʻokolokolo preclinical. ʻAʻole hana ʻia ia mau huahana ma lalo o ka lāʻau GMP, ʻaʻole i hoʻāʻo ʻia no ka hoʻohana kanaka, a ʻaʻohe ʻae hoʻoponopono (Palapala Peptide, 2025).

ʻO ka lepili wale nō e hoʻoholo i kekahi mea. Ma lalo o ka FD&C Kanawai, hoʻohana i manaʻo ʻia, aole ka hoole, hoʻomalu: he peptide i kūʻai ʻia a i manaʻo ʻia no ka ʻike, hoʻōla, lapaʻau, a i ʻole ka pale ʻana i ka maʻi i loko o ke kanaka he lāʻau lapaʻau ia ma lalo o ke kānāwai federal me ka nānā ʻole i ka ʻōlelo a ka lepili. Hoʻopili ka FDA i ka lepili a me ka hoʻopili, hoʻolaha a kūʻai aku, a me ka huina o na hoike (Palapala Peptide, 2025).

No laila e heluhelu i ka hale kūʻai holoʻokoʻa, ʻaʻole ka ʻaoʻao huahana. He mea hoʻolako e hoʻolaha ana i ke alakaʻi dosing, hōʻike hoʻohana kanaka, a i ʻole nā ​​koi ma mua a ma hope ua haʻi iā ʻoe i kāna mākeke i manaʻo ʻia, ka mea a kona wawae e olelo ai. Ua hoʻokaʻawale kahi mea hoʻolako nona nā mea waiwai ma ke kahua analytical a me ka hale hana noiʻi mai ka huahana kūʻai aku.

ʻAʻohe mea i loko o kēia alakaʻi he lāʻau lapaʻau a i ʻole ke alakaʻi dosing, a ʻaʻohe huahana i kuhikuhi ʻia ma ʻaneʻi i hāʻawi ʻia no ka hoʻohana kanaka.

ʻanuʻu 5: E ho'āʻo inā e kamaʻilio pono ka mea hoʻolako

ʻO ka ʻike maopopo ka mea e hāʻule ai ka hapa nui o nā mea hoʻolako, no ka mea, ua lilo ia i mea e hele ai. ʻO ka mea hoʻolako e kamaʻilio maikaʻi e haʻi iā ʻoe i ka mea i hōʻike ʻole ʻia e kāna palapala, inoa i ke keʻena hana i hana i nā hoʻokolohua, a hoʻopuka i nā moʻolelo hailona i hoʻopaʻa ʻia ma kahi o kahi helu hoʻomaʻemaʻe ʻole.

ʻEkolu mau hōʻailona pass/fail e lawe i ka hapa nui o ke kaumaha ma ka hōʻoia ʻana o ka mea hoʻolako peptide pae noiʻi:

  • Hōʻike i nā palena o kāna mau palapala ponoʻī. Ua ʻōlelo maʻalahi kahi mea hoʻolako e hele nei he palapala hōʻoia (KoA) hōʻoia i ka ʻike a me ke ana ʻana i ka maʻemaʻe no hoʻokahi hailona, a ʻaʻole hoʻokumu i ka sterility, nā pae endotoxin, a i ʻole kūpono no kekahi hoʻohana lāʻau lapaʻau. Hāʻawi ka mea hāʻawi hāʻule i ka CoA e hōʻike ʻoi aku ma mua o ka mea i hōʻike ʻia.

  • Kapa inoa i ke keʻena hoʻokolohua. Hoʻomaopopo ka mea kūʻai aku i ka lab a inā he hale a kūʻokoʻa paha. Ua kākau ka mea hāʻawi ʻole i ka "hoʻāʻo ʻia ʻekolu" me ka inoa ʻole o ka lab, he koi, aole he mooolelo.

  • Hoʻopuka i nā moʻolelo hailona i hoʻopaʻa ʻia. Hōʻike ka mea kūʻai aku i nā helu he nui me nā lā loiloi hiki iā ʻoe ke hoʻohālikelike i kāu hoʻouna. Hōʻike ka mea hāʻawi hemahema i hoʻokahi helu maʻemaʻe me ka nui ʻole a me ka lā ʻole.

No ke kōkua: e noi i ʻelua CoA mai nā ʻāpana like ʻole o ka peptide like a hoʻohālikelike i nā ʻaoʻao haumia, ʻaʻole wale ka poʻomanaʻo maʻemaʻe kiʻi.

He mākaʻikaʻi waeʻano pono: ma nā ʻaoʻao mea hoʻolako i nānā ʻia no kēia alakaʻi, ʻaʻohe mea i aʻo i ka poʻe heluhelu pehea e heluhelu ai i kahi CoA, he aha ke ʻano o ka hopena hala ʻole, a i ʻole pehea e ʻike ai i kahi CoA i hoʻopaʻa ʻia. ʻAʻole lawe ʻia ka ʻaoʻao mea hoʻolako kūlana kiʻekiʻe i ka lā hoʻolaha pae ʻaoʻao a i ʻole lā hoʻohou. E mālama i kahi ʻaoʻao ʻaʻole i kau ʻia ma ke ʻano he hōʻailona iā ia iho, a e nīnau pololei i ka mea hoʻolako i ka manawa i hoʻonui ʻia ai ka moʻolelo.

ʻanuʻu 6: E hoʻokomo i nā Koina ʻElima i loko o kahi Kaʻina Hana Hoʻonaʻauao Mea Hoʻolako

ka holo ʻana o ka hōʻoia ʻana mai ka hōʻoia ʻike ma o ka loiloi maʻemaʻe, nānā palapala, i manaoia-hoohana nana, mākaʻikaʻi ʻike, i kahi qua

Holo i nā pae ʻelima ma ke ʻano he kaʻina, ʻaʻole kahi papa inoa āu e hoʻohālike ai. ʻO ka hōʻoia ʻike ka mea mua, no ka mea, he mea ole ke kii maemae no ka mole hewa. ʻO ka loiloi maʻemaʻe e pili ana, a laila ka pūʻolo palapala, a laila nā mana hoʻohana i manaʻo ʻia, a laila ʻike maopopo. Hōʻole ʻia ka mea hoʻolako i hāʻule i kēlā me kēia pae ma ia pae; ʻaʻole ʻoe e lawe i mua e ʻike inā ʻoi aku ka maikaʻi o ke koena.

ʻO ke kumu e holo ai i kāu kaʻina ponoʻī ma mua o ka ʻae ʻana i ka helu pass i hōʻike ʻia e ka mea kūʻai aku ʻo ia ka liʻiliʻi o nā helu hāʻule i paʻi ʻia ma mua o ko lākou ʻike ʻia.. Ua paʻi nā papahana hoʻāʻo ʻaoʻao ʻekolu i nā ʻumi kaukani o nā hopena, komo 9,997 ʻO nā hue peptide i waiho ʻia no ka nānā ʻana, o ka BPC-157 i helu ai 756 nā hoʻokolohua ma waena 110 nā mea kūʻai aku (peptidesbeat.com hōʻike ma ka ʻikepili Finnrick, hōʻano hou ʻia ka waihona 2026-09-03). The widely repeated claim that roughly one in three samples fail basic expectations comes from that same single dataset, self-reported and not peer-reviewed, and the proportion has held stable over 12 i 14 months of reporting on the gray-market peptide boom. One dataset, echoed across outlets, is not independent corroboration.

That is the case for peptide supplier due diligence as a buyer-side control. Research-grade peptide supplier verification is something you perform against artifacts you inspect, and no documentation package substitutes for it. Hana ʻia ʻo Peptide

Nā hewa maʻamau e hōʻalo ai

Accepting a high purity figure as proof of identity. A 98% HPLC result says the main peak dominates the chromatogram; it does not say the peak is the right molecule. Identity comes from mass spectrometry, where the observed molecular weight matches the designed construct. Hoʻopili nā mea hoʻolako i nā mea ʻelua no ka mea ʻoi aku ka maʻalahi o kahi helu maʻemaʻe hoʻokahi ma mua o kahi moʻolelo analytical ʻelua ʻāpana. E noi i nā mea ʻelua, a e nānā i ka inoa o ke ala ʻike i ka nuipa i manaʻo ʻia.

Ka mālama ʻana i kahi helu wahi-pakeneka o UV e like me ka ʻikepili peptide net ma ke kaupaona. ʻIke UV ma 214 pane ʻo nm i ka iwi kuamoʻo peptide, no laila, hōʻike ka pākēneka i ka ʻāpana piko pili, ʻaʻole pehea ka nui o ka peptide i loko o ka hue. Kūlike koena, ʻAʻole ʻike ʻia ka wai a me ka paʻakai e ka mea ʻike akā aia ma ke koena. ʻO kēia ka lua maʻamau i ka palapala peptide o nā koi loiloi: ʻAʻole ʻike ʻia kahi helu wahi-pakeneka o UV ma ke kaumaha, a ʻo ka mea hoʻolako e hōʻike ana iā ia ma ke ʻano he kuhi hewa paha ia i ka hoʻāʻo ʻana a i ʻole ke hilinaʻi nei iā ʻoe.

Ke papa inoa ʻana me ka hōʻike ʻole ʻana i ke ʻano o ka pass a i ʻole ka hāʻule. Ma nā ʻaoʻao o nā mea hoʻolako i nānā ʻia no kēia alakaʻi, ʻIke ʻia nā chromatograms a me nā spectra ma ke ʻano he mea hoʻonaninani ma mua o nā hopena me nā koina ʻae ʻia. ʻO kahi kikoʻī hiki ʻole iā ʻoe ke hoʻohālikelike me kahi waiwai i hōʻike ʻia ʻaʻole ia he kikoʻī.

Ke waiho nei i nā ʻaoʻao me ka lā ʻole. ʻAʻole hiki ke hoʻopaʻa ʻia kahi CoA a i ʻole ʻaoʻao kikoʻī i ka nui, he hoʻoponopono hou ʻana a i ʻole ke keʻena hoʻokolohua, ʻo ia ka mea e hoʻohaʻahaʻa i ka traceability i loaʻa i ka palapala e hoʻolako.

Ki Takeaway: he kii maemae me ke ano ole, hailona, ʻO ke keʻena hana a me ka lā he koi, aole he ana.

Nīnau pinepine

Pehea e hiki ai iaʻu ke haʻi aku i kahi CoA i hoʻopaʻa ʻia a i hoʻopaʻi ʻia mai ka mea maoli?

E nānā inā pili ka helu hailona ma ka palapala hōʻoia me ka hailona ma ka lepili vial a me ka packing slip, a laila e ʻimi i kahi chromatogram a i ʻole spectrum kikoʻī i kēlā ʻāpana ma mua o kahi kiʻi i hoʻohana hou ʻia ma nā huahana. He palapala i kapa ʻole ʻia he hale hoʻokolohua hoʻāʻo a ʻaʻohe lā loiloi, a i ʻole nona ka chromatogram e ʻike hou ʻia ma lalo o ka helu lua, ʻaʻole i hōʻoia ʻia. ʻO ke noi ʻana i ka faila ʻikepili maka ma hope o ka hōʻike ʻo ia ka māka ikaika loa i loaʻa. E pili ana

Hiki iaʻu ke hōʻoia i ka ʻōlelo a ka mea hoʻolako ua hoʻāʻo kekahi ʻaoʻao ʻekolu i kāna peptides?

hapa. Hiki iā ʻoe ke hōʻoia i ke ola ʻana o ka hale hana i kapa ʻia, hāʻawi i ke ʻano i ʻōlelo ʻia, a hoopuka i na hoike ma ia ano. ʻO ka mea hiki ʻole i ka palapala ke hōʻike, ʻo ka hāpana i waiho ʻia mai ka hailona i loaʻa iā ʻoe. ʻAʻole manaʻo kuhi kēlā hakahaka: ʻO ka hōʻike ʻana e pili ana i ka peptide boom mākeke hina i ʻike ʻia ma kahi o kahi hapakolu o nā kaukani o nā huahana i kālailai ʻia ʻaʻole i hāʻule i nā loiloi kumu kumu., he mahele i hoololi ole ia ma luna o ka 12 i 14 mahina o ka ʻohi ʻikepili. ʻO ka hoʻāʻo kūʻokoʻa o kahi laʻana i mālama ʻia mai kāu loaʻa ponoʻī ke ala wale nō e pani ai.

He aha kaʻu e hana ai inā hōʻike ka CoA i ka maʻemaʻe me ka ʻole o ka chromatogram a i ʻole ka hailona?

E noi i nā mea hana i nalowale ma mua o ka loiloi ʻana i ka helu. He kiʻi maʻemaʻe me ke ʻano ʻole, ka mea hoʻomaopopo he nui, a ʻaʻole hiki ke ʻimi ʻia kahi chromatogram kākoʻo i kekahi mea, no laila, hana ia ma ke ʻano he ʻōlelo kūʻai aku ma mua o ka hōʻike analytical. E hoʻomaopopo hoʻi i ke ʻano o ke kiʻi maʻemaʻe: ke alakaʻi o ka peptide dossier a ka FDA hoʻonohonoho i hoʻokahi paepae haumia pili peptide o 0.10% o ka laau lapaau no ke ano haumia, he koi hoʻohālikelike a ʻaʻole he hōʻoia ʻike. Halawai i kou palapala hōʻoia peptide o nā koi ana ʻo ia hoʻi ka paʻa ʻana i ka ʻike, ka maemae, a me ka loaʻa ʻana ma ke ʻano he moʻolelo kaʻawale, ʻaʻole hoʻokahi pākēneka poʻomanaʻo.

Ke hoʻololi nei ka lepili noiʻi-hoʻohana-wale i ke kūlana kānāwai o ka mea hoʻolako?

Hoʻololi ia i ka paʻi ʻana ma mua o ka hoʻoponopono ʻana i ka nīnau. Hōʻike ka lepili noiʻi-hoʻohana-wale i ka noi ʻana o ka huahana, a loiloi nā mea hoʻoponopono i ka hana a ka mea hoʻolako e kūʻē i kēlā manaʻo. E like me ka hōʻike ʻana o kekahi loiloi kānāwai o ka wahi hina, hoʻohana i manaʻo ʻia, aole ka hoole, hoʻomalu. Ma ka hana, hoʻohana ka noiʻi i ka lepili peptide wale nō he hōʻailona hōʻailona: he mea hoʻolako e hoʻokaʻawale mau ana i nā mea noiʻi mai ka mea kūʻai aku, a ʻaʻole hoʻopuka i nā kuhikuhi dosing a i ʻole hoʻohana kanaka, ʻoi aku ka maʻalahi o ka hoʻokō ʻana ma mua o ka mea kūʻai kūʻai kūʻē i kāna lepili ponoʻī. ʻAʻole kēia he ʻōlelo aʻo kānāwai; e kukakuka no kou mana.

Ka hopena

ʻO nā pae ʻelima hoʻokahi maʻamau: hoʻokaʻawale i ka ʻike mai ka maʻemaʻe, e heluhelu i kela a me keia koi maemae no kona ano, hailona, lab a me ka lā, e nānā i ka pūʻolo palapala e kūʻē iā ALCOA+, e mālama i nā mana i hoʻohana ʻia ma ke ʻano he puka hōʻoia, a nānā i ka pane ʻana o ka mea hoʻolako i kahi nīnau ʻino. ʻO ka hoʻomaʻamaʻa pono ʻana o ka mea hoʻolako peptide ʻaʻole ia he loiloi hoʻokahi wale nō akā ʻo ka hana o ka makemake ʻana i kahi mea kūʻai aku hiki ke nānā ʻia nā mea waiwai ma luna o ka mea hiki ke manaʻoʻiʻo wale ʻia.. He CoA kiko'ī nui e kapa ana i ke keʻena hoʻokolohua, ʻo ke ʻano analytical a me ka lā hōʻike e hāʻawi iā ʻoe i kahi mea e waiho ai, e hoʻohālikelike i nā pūʻulu a me ka lima i kahi hoa hana; ʻO ka pakeneka maʻemaʻe me ka ʻole o ia pōʻaiapili e hāʻawi iā ʻoe i kahi mea e nānā ai.

Inā makemake ʻoe e holo i ka framework e kūʻē i kahi pūʻolo maoli, noi i kahi laʻana CoA pūʻolo a i ʻole e kamaʻilio me kahi loea loea. ʻO nā hana haʻahaʻa haʻahaʻa ʻelua e ʻae iā ʻoe e hoʻāʻo i ka palapala ma mua o kekahi hoʻoholo kūʻai.

Hōʻike: Loaʻa i ka MOL Changes kahi hoihoi pāʻoihana i nā kūlana maikaʻi o ka peptide a hāʻawi i nā peptides noiʻi-grade me nā palapala analytical kikoʻī kikoʻī.. ʻAʻohe mea i loko o kēia alakaʻi he lāʻau lapaʻau a i ʻole ke alakaʻi dosing, a no ka noiʻi wale nō nā huahana a pau i kūkākūkā ʻia.

Nānā ʻia e ka hui ʻenehana MOL Changes. E kamaʻilio me kahi ʻoihana kūpono ma mua o ka hoʻoholo ʻana e pili ana i nā mea noiʻi.

Zejun Peng

Zejun Peng

Luna ʻenehana Nui; ʻO ka mea akamai i ka peptide Synthesis Kaʻike kumu: ʻO ka peptide synthesis paʻakikī, nā hoʻololi ʻana o ka amino acid kūlohelohe, a me ke kūkulu ʻana i nā peptides cyclic a me nā peptides stapled.

moʻokalaleo:He ʻike nui ʻo Zejun Peng i ka kemika kūlohelohe a me ka synthesis peptide. Maikaʻi ʻo ia i ka hoʻohana ʻana o ka solid-phase peptide synthesis (SPSS) a me ka peptide synthesis wai (LPPS), a akamai loa i ka lanakila ʻana i nā "paʻakikī loa-e-synthesize sequences" (e like me nā peptides ultra-long-chain, nā kaʻina hydrophobic kiʻekiʻe, a me ka pelu ana i na mea paa disulfide lehulehu). Ma lalo o kāna alakaʻi, ua lanakila ka hui i nā bottlenecks ʻenehana i kekahi mau hoʻololi kūikawā (e like me ka N-methylation, PEGylation, a me ka lepili fluorescent), ka mālama ʻana i ka helu kūleʻa synthesis o luna 98%.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana